NCT07136844 Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
| NCT ID | NCT07136844 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Liege |
| Condition | Neuromuscular Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-03-29 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2024-03-29 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement. Conducted at the Centre de Référence Liégeois des Maladies Neuromusculaires in Liège, Belgium, the study will enroll 300 ambulant patients, including individuals with neuromuscular disorders and obesity. Using the Syde® wearable device, the study aims to continuously monitor motor function in real-life settings over a period of up to two years. The primary objective is to evaluate the utility of digital mobility outcomes, such as the 95th centile of stride velocity (SV95C), as reliable and objective endpoints for future clinical trials.
Eligibility Criteria
Inclusion Criteria: * Ambulant patients (i.e. able to walk 10 meters without assistance) * Confirmed diagnosis by the investigator based on current gold standard in his/her disease (genetic testing, clinical criteria, etc.) * Myotonic dystrophy type 1 (DM1) and Charcot-Marie-Tooth (CMT) patients should present sensitive of motor signs on physical examination. * Myasthenic patients should be seropositive, and Myasthenia Gravis Foundation of America (MGFA) class II to IV. * Patient with morbid obesity (Body Mass Index\> or = 35 at inclusion visit). * Signed informed consent form by patient him/herself and patient willing and able to comply with all study procedures. Exclusion Criteria: * Non-ambulant patients * Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed * Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs * A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion * Patients who are participating in an interventional clinical trial * Pregnant or breastfeeding women
Contact & Investigator
Laurent Servais, MD
PRINCIPAL INVESTIGATOR
Centre Hospitalier Universitaire de Liege
Frequently Asked Questions
Who can join the NCT07136844 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neuromuscular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07136844 currently recruiting?
Yes, NCT07136844 is actively recruiting participants. Contact the research team at Nicolas.Bovy@citadelle.be for enrollment information.
Where is the NCT07136844 trial being conducted?
This trial is being conducted at Liège, Belgium.
Who is sponsoring the NCT07136844 clinical trial?
NCT07136844 is sponsored by Centre Hospitalier Universitaire de Liege. The principal investigator is Laurent Servais, MD at Centre Hospitalier Universitaire de Liege. The trial plans to enroll 300 participants.